Polymers for reversing heparin-based anticoagulation

• US 10,111,902 B2
• Filed: 02/23/2015
• Issued: 10/30/2018
• Est. Priority Date: 06/01/2011
• Status: Active Grant

• Current Assignee: University of British Columbia
• Original Assignee: University of British Columbia
• Inventors: Kizhakkedathu, Jayachandran N., Shenoi, Rajesh A., Carter, Cedric J., Brooks, Donald E.
• Primary Examiner(s): Orwig, Kevin S
• Assistant Examiner(s): Cao, Ping
• Application Number:
  US14/629,408
• Publication Number:
  US 20150224244A1
• Time in Patent Office: 1,345 Days
• Field of Search: None
• CPC Class Codes: A61K 31/765 Polymers containing oxygen
• CPC Class Codes: A61K 31/785 Polymers containing nitrogen
• CPC Class Codes: A61K 31/795 Polymers containing sulfur
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61M 1/3675 Deactivation
• CPC Class Codes: A61M 1/3679 by absorption A61M1/3675 takes precedence
• CPC Class Codes: A61M 2202/0021 removed from and reintroduced into the body, e.g. after treatment
• CPC Class Codes: A61M 2202/0413 Blood
• CPC Class Codes: A61M 2202/0478 Heparin
• CPC Class Codes: B01D 15/36 involving ionic interaction
• CPC Class Codes: C08G 2340/00 Filter material
• CPC Class Codes: C08G 73/024 Polyamines containing oxygen in the form of ether bonds in the main chain
• CPC Class Codes: C08L 71/02 Polyalkylene oxides

Abstract

Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.

Claims

1. A controlled release delivery device comprising:

a support having a surface;

a heparin binding polymer attached to the surface, the heparin binding polymer comprising;

a first dendritic polyol;

one or more cationic moieties, at least one of the one or more cationic moieties attached to the first dendritic polyol; and

at least one cleavage site; and

heparin bound to the heparin binding polymer, wherein the heparin binding polymer has the structure of Formula (I);

2. The controlled release delivery device of claim 1, wherein the surface forms part of a bead.

3. The controlled release delivery device of claim 1, wherein the surface comprises a flat surface.

4. The controlled release delivery device of claim 1, wherein the surface forms at least a portion of a cartridge.

5. The controlled release delivery device of claim 1, wherein the heparin binding polymer is attached to the surface via an acetal bond or a ketal bond.

6. The controlled release delivery device of claim 1, wherein the heparin binding polymer is attached to the surface via a disulfide bond.

7. The controlled release delivery device of claim 1, wherein the heparin binding polymer comprises a protective moiety covalently attached to the first dendritic polyol.

8. The controlled release delivery device of claim 1, wherein the heparin binding polymer comprises a second dendritic polyol, wherein the at least one cleavage site links the first dendritic polyol to the second dendritic polyol.

9. A controlled release delivery device comprising:

a support having a surface;

a heparin binding polymer attached to the surface, the heparin binding polymer comprising;

a first dendritic polyol;

one or more cationic moieties, at least one of the one or more cationic moieties attached to the first dendritic polyol; and

at least one cleavage site; and

heparin bound to the heparin binding polymer, wherein the heparin binding polymer has the structure of Formula (II);

10. The controlled release delivery device of claim 9, wherein the surface forms part of a bead.

11. The controlled release delivery device of claim 9, wherein the surface comprises a flat surface.

12. The controlled release delivery device of claim 9, wherein the surface forms at least a portion of a cartridge.

13. The controlled release delivery device of claim 9, wherein the heparin binding polymer is attached to the surface via an acetal bond or a ketal bond.

14. The controlled release delivery device of claim 9, wherein the heparin binding polymer comprises a protective moiety covalently attached to the first dendritic polyol.

15. The controlled release delivery device of claim 9, wherein the heparin binding polymer comprises a second dendritic polyol, wherein the at least one cleavage site links the first dendritic polyol to the second dendritic polyol.